Two of them received targeted therapy (patient #8 with low-grade glioma and proven pathogenic variant in BRAF gene in the tumor tissue received MEK and BRAF inhibitors; patient #13 with NF2 was treated by VEGF and mTOR inhibition due to the known genetic disease) contrasted to other patients who received conventional chemotherapy. Here, MTOR is linked to central nervous system cancer.